TX-POWER-COSTS-INC
17.3.2021 11:02:10 CET | Business Wire | Press release
Brookfield Renewable Ireland Limited (“BRIL” or “Brookfield Renewable”) has gone live with PCI’s Enterprise Platform to manage its customer billing requirements in the Irish energy market.
As part of its partnership with Brookfield Renewable, PCI deployed its specifically tailored, cloud-based, integrated platform to replace the Irish business’ legacy system and several in-house applications. The new Customer Billing Solution implemented by PCI enables Brookfield Renewable to:
- Manage complex bilateral contracts, including power purchase agreements (PPAs)
- Leverage PCI’s settlements calculation business rules engine to perform billing allocation
- Perform counterparty checkouts and meter data management (MDM)
- Interface with upstream and downstream (physical, telemetered, and accounting) systems
- Maintain comprehensive auditability with all data versions
- Automate invoice creation and management workflows
- Drill-down and quickly extract data to perform reporting
BRIL Chief Commercial Officer Ciaran O'Brien noted, “We are excited at the launch of our new cloud-based customer billing system which will be transformational for our renewable energy business, bringing increased flexibility and supporting further growth with a scalable, best-in-class solution.” Adding, “We are proud to partner with PCI on this project and appreciate the professional collaboration with our team for an on-time and on-budget delivery.”
“We have found a great partner in Brookfield Renewable, one that has a matching ethos and customer-centric mindset. The successful go-live represents a major milestone for PCI’s global, remote software deployments that feature 24x7 operations,” said PCI Vice President Shailesh Mishra.
As part of the next phase of this project, Brookfield Renewable’s Irish business plans to leverage the PCI Platform to provide its customers with a dedicated application for on-demand access to energy data and enhanced reporting. PCI’s Platform offers unmatched functionality for renewable energy players to optimize their portfolios, including co-optimization of Energy Storage Systems (ESS) in wholesale power markets. PCI works with numerous renewable energy providers, including BHE Renewables, RWE Renewables, Iberdrola, Acciona, Xcel Energy, DTE Energy, and others.
About Brookfield Renewable
Brookfield Renewable operates one of the world’s largest publicly traded, pure-play renewable power platforms. Its portfolio consists of hydroelectric, wind, solar, distributed generation, and storage facilities in North America, South America, Europe, and Asia, and totals approximately 20,000 megawatts of installed capacity and an approximately 23,000-megawatt development pipeline.
Brookfield Renewable’s Irish onshore wind portfolio is a fully integrated development, operations, and renewable energy solutions business with 365 MW of operating capacity and a significant onshore wind development pipeline. Further information is available at www.brookfield.com/our-businesses/renewable-power .
About Power Costs, Inc. (PCI)
PCI is the leading provider of energy trading software, superior customer support, and value-added services for energy companies worldwide. Founded in 1992, PCI continues to refine and develop new solutions that meet the ever-evolving needs of its clients which include investor-owned, municipal, and cooperative utilities, renewable energy companies, energy marketers and traders, as well as independent power producers. PCI optimizes more than half the power generated in North America and more than 60% of Fortune 500 Utilities in the U.S. are PCI customers. The firm is privately held and based in Norman (OK) with regional offices in Houston (TX), Raleigh (NC), and Mexico City. To learn more, please visit www.powercosts.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005052/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom